Company expands strategic focus into one of oncology’s most urgent supportive-care challengesJericho, New York, April 02, 2026 (GLOBE NEWSWIRE) ...
Curanex Pharmaceuticals, Inc. CURX on Thursday said it is expanding its drug development pipeline. Pipeline Expansion Adds ...
Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the ...
"Our project is innovative in its use of advanced epigenetic techniques combined with a novel preclinical model of PDAC survivorship," Dr. Arneson-Wissink said. "Together, these tools allow us to ...
Until recently, the root cause of cachexia was identified as the inflammatory mediators produced either by the tumour itself ...
Cachexia, defined as a loss of body weight, fat, and muscle mass that occurs in patients with chronic diseases, including cancer, remains a notable clinical challenge. With limited viable treatment ...
Cancer cachexia is a multifactorial syndrome marked by a severe loss of body weight due primarily to the wasting of skeletal muscle and adipose tissue. This syndrome is often accompanied by systemic ...
Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients. Maintaining good health and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results